Abstract
Background and objective: To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment. patients and methods: This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included. results: Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 Log MAR (range: 0 Log MAR to 0.8 Log MAR) with a mean follow-up of 25.2 months ± 6.8 months. conclusions: IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, non response to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment.
Original language | English |
---|---|
Pages (from-to) | 1095-1105 |
Number of pages | 11 |
Journal | Ophthalmic Surgery Lasers and Imaging Retina |
Volume | 47 |
Issue number | 12 |
DOIs | |
State | Published - 12 2016 |